Greg Freiherr, Industry Consultant
Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | Radiology Imaging | June 15, 2016

How the Trump Candidacy Might Energize Men’s Healthcare

Trump, PSA, prostate cancer

Image courtesy of Pixabay.

Personalized medical care conjures an image of exactness. Precision. Its realization was once believed attainable through sequencing the human genome. But when that didn’t happen, the concept was redefined as healthcare tailored to the individual.

Finding disease at its earliest stages through screening is a big part of it. The widespread use of mammography and testing for the gene associated with breast cancer have gone a long way in this regard for women’s health. But how to achieve similar gains for men?

Donald Trump’s candidacy might provide the answer.

Trump may not have actually drawn more people to the GOP, as he has claimed over and over. But the presumptive Republican nominee unquestionably has brought voters into the political process earlier than ever before.

Might the segment of the electorate energized by Trump be harnessed to propel the technological development and ultimately widespread use of a screening test for prostate cancer? A major segment of Trump supporters — middle-aged men — is at risk of developing this disease.

Politics can be the fuel for technological development. Lobbyists can promote funding for research, technological development and the reimbursement of procedures. Lobbying may be especially effective when supported by grassroots efforts.

Nothing so incentivizes people like fear, a fact proven by Trump. And there is plenty of reason to be afraid of prostate cancer. According to the U.S. government, prostate cancer is the most common non-skin cancer and the second leading cause of cancer-related death in men in the United States. It was estimated that, in 2014, 233,000 men in the U.S. would be diagnosed with prostate cancer. Nearly 29,500 would die of the disease.

 

The “Unprotected”

As February drew to a close, Peggy Noonan of the Wall Street Journal wrestled with the incomprehensibility of Trump as the enunciated the idea of “protection” as an explanation GOP nominee and what had propelled him to that point. She opined that the protected in America — the elite who have money, live in safe neighborhoods, have functioning families, and whose kids go to good schools — make public policy. The unprotected, who have none of these and instead lived in the rougher world created for them, had begun to push back — powerfully, she wrote.

According to a survey from RAND Corporation, voters who agreed with the statement “people like me don't have any say about what the government does” were 86.5 percent more likely to prefer Trump.

Judging from Trump’s success, the unprotected want change. After the presidential election, will they acquiesce? Or might their wants be channeled to other causes? Might they be mobilized to support the development and use of a screening tool for prostate cancer? What will be needed for that to happen?

 

Better Testing Needed

One thing is for sure. The current blood test built on measuring prostate-specific antigen (PSA) needs to be replaced. Although the likelihood of prostate cancer increases with the rising levels of PSA, abnormal values have been associated with benign conditions, according to Harvard Medical School. PSA testing is so woefully inadequate that many advisory groups recommend against routine screening for prostate cancer. (A large American study found that screening for prostate cancer did not reduce the chance of dying from the disease.1)

Blood, tissue and urine samples may contain better biomarkers than PSA. Ongoing research is looking into those possibilities. And there are a number of imaging possibilities, including PET, SPECT and MRI.

Where might this technological potential take us? Probably nowhere, unless driven politically. To be successful, a campaign to develop and utilize a screening test for prostate cancer must resonate with a substantial block of voters.

The segment of the electorate energized by the Trump candidacy might be that block.

 

Additional reading:

1Andriole GL, Crawford ED, et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J National Cancer Institute 2012; 104:125.

Editor's note: This is the third blog in a four-part series on screening. The first blog, “Screening: How New Looks at Old Modalities Might Turn Imaging Upside Down,” can be found here. The second blog, “Why Developing Multiple Screening Technologies is a Must,” can be found here.

Related Content

A patient implanted with the Axonics System can undergo MRI examinations safely with radio frequency (RF) Transmit Body or Head Coil under the conditions outlined in the Axonics MRI Conditional Guidelines.

A patient implanted with the Axonics System can undergo MRI examinations safely with radio frequency (RF) Transmit Body or Head Coil under the conditions outlined in the Axonics MRI Conditional Guidelines.

News | Magnetic Resonance Imaging (MRI) | July 02, 2020
July 2, 2020 — Axonics Modulation Technologies, Inc., a medical technology company that has developed and is commerci
This data represents wave 2 of a QuickPoLL survey conducted in partnership with an imagePRO panel created by The MarkeTech Group (TMTG), regarding the effects of COVID-19 on their business

Getty Images

Feature | Coronavirus (COVID-19) | July 01, 2020 | By Melinda Taschetta-Millane
A 3-D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Volume flow as a function of color flow gain (at a single testing site). For each row the color flow c-plane and the computed volume flow are shown as a function of color flow gain. The c-plane is shown for four representative gain levels, whereas the computed volume flow is shown for 12–17 steps across the available gain settings. Flow was computed with (solid circles on the graphs) and without (hollow circles on the graphs) partial volume correction. Partial volume correction accounts for pixels that are only partially inside the lumen. Therefore, high gain (ie, blooming) does not result in overestimation of flow. Systems 1 and 2 converge to true flow after the lumen is filled with color pixel. System 3 is nearly constant regarding gain and underestimates the flow by approximately 17%. Shown are mean flow estimated from 20 volumes, and the error bars show standard deviation. Image courtesy of the journal Radiology

News | Ultrasound Imaging | July 01, 2020
July 1, 2020 — A 3-D ultrasound
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for its head CT scan product qER. The US Food and Drug Administration's decision covers four critical abnormalities identified by Qure.ai's emergency room product.
News | Artificial Intelligence | June 30, 2020
June 30, 2020 — Imaging Artificial Intelligence (AI) provider Qure.ai announced its first US FDA 510(k) clearance for
Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

Cardiac MR can offer data above and beyond anatomical imaging, which is the main reason why this system was installed at Baylor Scott White Heart Hospital in Dallas. The system is a dedicated heart MRI scanner.

News | Pediatric Imaging | June 29, 2020
June 29, 2020 — A type of smart magnetic r...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

News | Coronavirus (COVID-19) | June 26, 2020
June 26, 2020 — In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association wit
The American College of Radiology (ACR) Center for Research and Innovation (CRI) is pleased to announce the development of the COVID-19 Imaging Research Registry (CIRR), an effort by the ACR CRI and the ACR Data Science Institute in collaboration with the ACR and the Society of Thoracic Radiology (STR). Sharyn Katz, M.D., director of research for thoracic radiology at the University of Pennsylvania, chairs the effort’s multiple-disciplinary steering committee, which includes representation from across the i

Getty Images

News | Coronavirus (COVID-19) | June 25, 2020
June 25, 2020 — The American College of Radiology (ACR) Center for R